Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 396

1.

Economic evaluation of oseltamivir phosphate for postexposure prophylaxis of influenza in long-term care facilities.

Risebrough NA, Bowles SK, Simor AE, McGeer A, Oh PI.

J Am Geriatr Soc. 2005 Mar;53(3):444-51.

PMID:
15743287
2.

Management of influenza in adults older than 65 years of age: cost-effectiveness of rapid testing and antiviral therapy.

Rothberg MB, Bellantonio S, Rose DN.

Ann Intern Med. 2003 Sep 2;139(5 Pt 1):321-9.

PMID:
12965940
3.

Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999-2000.

Bowles SK, Lee W, Simor AE, Vearncombe M, Loeb M, Tamblyn S, Fearon M, Li Y, McGeer A; Oseltamivir Compassionate Use Program Group.

J Am Geriatr Soc. 2002 Apr;50(4):608-16.

PMID:
11982659
4.

Experience with oseltamivir in the control of a nursing home influenza B outbreak.

Parker R, Loewen N, Skowronski D.

Can Commun Dis Rep. 2001 Mar 1;27(5):37-40. English, French.

5.

Cost-effectiveness of newer treatment strategies for influenza.

Smith KJ, Roberts MS.

Am J Med. 2002 Sep;113(4):300-7.

PMID:
12361816
6.

Systematic review and economic decision modelling for the prevention and treatment of influenza A and B.

Turner D, Wailoo A, Nicholson K, Cooper N, Sutton A, Abrams K.

Health Technol Assess. 2003;7(35):iii-iv, xi-xiii, 1-170. Review.

7.

Antiviral agents for influenza: a comparison of cost-effectiveness data.

Lynd LD, Goeree R, O'Brien BJ.

Pharmacoeconomics. 2005;23(11):1083-106. Review.

PMID:
16277546
8.

Oseltamivir for influenza postexposure prophylaxis: economic evaluation for children aged 1-12 years in the U.S.

Talbird SE, Brogan AJ, Winiarski AP.

Am J Prev Med. 2009 Nov;37(5):381-8. doi: 10.1016/j.amepre.2009.08.012.

PMID:
19840692
9.

Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation.

Tappenden P, Jackson R, Cooper K, Rees A, Simpson E, Read R, Nicholson K.

Health Technol Assess. 2009 Feb;13(11):iii, ix-xii, 1-246. doi: 10.3310/hta13110. Review.

10.

Antiviral drugs in influenza: an adjunct to vaccination in some situations.

[No authors listed]

Prescrire Int. 2006 Feb;15(81):21-30.

PMID:
16548114
11.

Effect of timing of amantadine chemoprophylaxis on severity of outbreaks of influenza a in adult long-term care facilities.

Rubin MS, Nivin B, Ackelsberg J.

Clin Infect Dis. 2008 Jul 1;47(1):47-52. doi: 10.1086/588658.

PMID:
18484879
12.
13.

Economic analysis of influenza vaccination and antiviral treatment for healthy working adults.

Lee PY, Matchar DB, Clements DA, Huber J, Hamilton JD, Peterson ED.

Ann Intern Med. 2002 Aug 20;137(4):225-31.

PMID:
12186512
14.
15.

Cost-effectiveness of treating influenzalike illness with oseltamivir in the United States.

Talbird SE, Brogan AJ, Winiarski AP, Sander B.

Am J Health Syst Pharm. 2009 Mar 1;66(5):469-80. doi: 10.2146/ajhp080296.

PMID:
19233995
16.

Pharmacoeconomic assessment of oseltamivir in treating influenza--the case of otherwise healthy Danish adolescents and adults.

Vindt Holm M, Gyldmark M, Holme Hansen E.

Pharm World Sci. 2004 Dec;26(6):339-45.

PMID:
15683104
17.

Summaries for patients. Cost-effective management of flu in adults older than 65 years of age.

[No authors listed]

Ann Intern Med. 2003 Sep 2;139(5 Pt 1):I27. No abstract available.

PMID:
12965955
18.

Post-exposure influenza prophylaxis with oseltamivir: cost effectiveness and cost utility in families in the UK.

Sander B, Hayden FG, Gyldmark M, Garrison LP Jr.

Pharmacoeconomics. 2006;24(4):373-86.

PMID:
16605283
19.
20.

Oseltamivir: new preparation. An antiviral agent with little impact on influenza.

[No authors listed]

Prescrire Int. 2003 Jun;12(65):85-8.

PMID:
12825569

Supplemental Content

Support Center